431 related articles for article (PubMed ID: 27241239)
41. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.
Mendell JR; Barohn RJ; Freimer ML; Kissel JT; King W; Nagaraja HN; Rice R; Campbell WW; Donofrio PD; Jackson CE; Lewis RA; Shy M; Simpson DM; Parry GJ; Rivner MH; Thornton CA; Bromberg MB; Tandan R; Harati Y; Giuliani MJ;
Neurology; 2001 Feb; 56(4):445-9. PubMed ID: 11222785
[TBL] [Abstract][Full Text] [Related]
42. The role of IVIg in autoimmune neuropathies: the latest evidence.
Hughes R
J Neurol; 2008 Jul; 255 Suppl 3():7-11. PubMed ID: 18685920
[TBL] [Abstract][Full Text] [Related]
43. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with diabetes mellitus - treatment with intravenous immunoglobulins: A systematic review.
Andrusiów S; Pawlak Z; Stańczykiewicz B; Bogunia-Kubik K; Koszewicz M
Biomed Pharmacother; 2023 Aug; 164():114974. PubMed ID: 37290187
[TBL] [Abstract][Full Text] [Related]
44. Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy.
Kapoor M; Carr A; Foiani M; Heslegrave A; Zetterberg H; Malaspina A; Compton L; Hutton E; Rossor A; Reilly MM; Lunn MP
Eur J Neurol; 2022 Nov; 29(11):3347-3357. PubMed ID: 35837802
[TBL] [Abstract][Full Text] [Related]
45. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.
Kokubun N; Sada T; Yuki N; Okabe M; Hirata K
Eur Neurol; 2013; 70(1-2):65-9. PubMed ID: 23796651
[TBL] [Abstract][Full Text] [Related]
46. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
[TBL] [Abstract][Full Text] [Related]
47. Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations.
Dalakas MC; Latov N; Kuitwaard K
Expert Rev Neurother; 2022; 22(11-12):953-962. PubMed ID: 36645654
[TBL] [Abstract][Full Text] [Related]
48. Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis.
Anderson-Smits C; Ritchey ME; Huang Z; Chavan S; Souayah N; Ay H; Layton JB
Neurol Ther; 2023 Aug; 12(4):1119-1132. PubMed ID: 37171778
[TBL] [Abstract][Full Text] [Related]
49. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.
Adrichem ME; Bus SR; Wieske L; Mohammed H; Verhamme C; Hadden R; van Schaik IN; Eftimov F
Eur J Neurol; 2020 Mar; 27(3):506-513. PubMed ID: 31571349
[TBL] [Abstract][Full Text] [Related]
50. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.
van Schaik IN; Winer JB; de Haan R; Vermeulen M
Lancet Neurol; 2002 Dec; 1(8):491-8. PubMed ID: 12849334
[TBL] [Abstract][Full Text] [Related]
51. The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy.
Bohn AB; Nederby L; Harbo T; Skovbo A; Vorup-Jensen T; Krog J; Jakobsen J; Hokland ME
Eur J Neurol; 2011 Jun; 18(6):919-24. PubMed ID: 21219545
[TBL] [Abstract][Full Text] [Related]
52. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
Chan YC; Allen DC; Fialho D; Mills KR; Hughes RA
J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):114-6. PubMed ID: 16361609
[TBL] [Abstract][Full Text] [Related]
53. Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Silsby M; Yiannikas C; Ng K; Kiernan MC; Fung VSC; Vucic S
Muscle Nerve; 2022 Jan; 65(1):43-50. PubMed ID: 34383335
[TBL] [Abstract][Full Text] [Related]
54. Management of chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA
Drugs; 2003; 63(3):275-87. PubMed ID: 12534332
[TBL] [Abstract][Full Text] [Related]
55. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies.
Dalakas MC
J Peripher Nerv Syst; 2012 May; 17 Suppl 2():34-9. PubMed ID: 22548621
[TBL] [Abstract][Full Text] [Related]
56. Intravenous immunoglobulin (IVIG) in the treatment of chronic demyelinating polyradiculoneuropathy.
Van den Bergh PY
Acta Neurol Belg; 2001 Sep; 101(3):147-51. PubMed ID: 11817262
[No Abstract] [Full Text] [Related]
57. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
58. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
59. [Treatment's initiation in chronic inflammatory demyelinating polyradiculopathy (CIDP)].
Uzenot D; Azulay JP; Pouget J
Rev Neurol (Paris); 2007 Sep; 163 Spec No 1():3S68-76. PubMed ID: 18087233
[TBL] [Abstract][Full Text] [Related]
60. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update.
Nobile-Orazio E; Gallia F; Tuccillo F; Terenghi F
Curr Opin Neurol; 2010 Oct; 23(5):519-23. PubMed ID: 20689427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
